POWERED BY

Boltz raises $110M in Series A funding

PublishedNovember 19, 2026

Boltz has announced $110 million in Series A funding led by Bessemer Venture Partners. The company has signed partnerships with six of the world’s 20 largest pharmaceutical companies, while molecular token usage among paying customers has increased 50-fold since June.

The funding will support further investment in computing capacity and data, help meet growing demand from partners and enable the company to expand its team. Boltz aims to make advanced molecular design tools more accessible to scientists developing future medicines.

Founded in 2025, Boltz was established on the premise that AI could shift a greater share of molecular discovery from physical experiments to computational methods, enabling scientists to design medicines at greater scale, speed and quality.

In June 2026, the company released its first proprietary models, BoltzMol-1 and BoltzProt-1. Using these models, Boltz identified small-molecule hits and designed protein binders for most of the challenging targets it pursued, with substantially less time and cost than traditional approaches or previous models would have required.

Boltz aims to make these models accessible to scientists rather than limiting their use to a single company’s proprietary research pipeline or restrictive strategic partnerships.

In January 2026, the company launched Boltz Lab, providing scientists and AI agents with access to its latest models. Thousands of scientists registered within the first few weeks. The platform now serves pharmaceutical, biotechnology and industrial companies, including six of the world’s 20 largest pharmaceutical companies. These include Pfizer, GSK, Takeda and BMS.

Boltz expects further improvements in AI model capabilities. Its upcoming models are already showing substantial improvements in the quality of generated molecules. The company’s long-term objective is to enable scientists to move from a therapeutic hypothesis to a molecule ready for human testing using computational tools. Achieving this will require continued advances in models, as well as significant investment in computing capacity and data.

Bessemer Venture Partners led the Series A round. Andrew Hedin and Byron Deeter will join the company’s investor group, bringing experience in biotechnology and AI.

Existing investors have also increased their commitments, including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures. New investors include Greycroft, F-Prime Capital, Hummingbird and Benchling, alongside other participants.

In just over a year, Boltz has grown from a small group of MIT researchers into a team of 40 scientists and engineers. Team members come from leading AI research laboratories, academic institutions, technology, finance, pharmaceutical and biotechnology companies.

The team is responsible for advancing the company’s models, developing its products and supporting scientists in applying the technology to their research.

Boltz plans to continue expanding its team and developing the next generation of molecular models. The company is seeking candidates interested in advancing molecular AI and making these tools accessible to scientists.

Source